Bivalent Vaccine Provides Added Protection Against BA.5, XBB/XBB.1.5
THURSDAY, Jan. 26, 2023 (HealthDay News) -- Bivalent vaccines seem to provide additional protection against symptomatic BA.5 and XBB/XBB.1.5 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron sublineages, according to research published in the Jan. 27 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Ruth Link-Gelles, Ph.D., from the CDC in Atlanta, and colleagues analyzed data from the Increasing Community Access to Testing national pharmacy program for SARS-CoV-2 testing to estimate the vaccine effectiveness of updated (bivalent) mRNA COVID-19 vaccines against symptomatic infection caused by BA.5-related and XBB/XBB.1.5-related sublineages among adults during Dec. 1, 2022, to Jan. 13, 2023. A total of 29,175 nucleic acid amplification tests were included from adults who had previously received two to four monovalent COVID-19 vaccine doses.
The researchers found that for adults aged 18 to 49 years, the relative vaccine effectiveness of a bivalent booster given two to three months earlier was 52 and 48 percent against symptomatic BA.5 infection and against symptomatic XBB/XBB.1.5 infection, respectively, compared with no bivalent booster.
"All persons should stay up to date with recommended COVID-19 vaccines, including receiving a bivalent booster dose when eligible," the authors write.
Related Posts
Las vacunas contra la gripe se rezagan en los estados con una baja adopción de las vacunas contra la COVID
JUEVES, 16 de junio de 2022 (HealthDay News) -- Las vacunas contra la gripe para...
Who Needs to Worry About the Polio ‘Emergency’?
TUESDAY, Sept. 13, 2022 (HealthDay News) -- Even though New York Governor Kathy...
AHA News: New York Woman Who Saved Husband’s Life Inspires Others to Learn CPR
TUESDAY, Aug. 31, 2021 (American Heart Association News) -- Lisa Wiles was in...
Health Highlights: Jan. 27, 2022
Studies ease concerns over COVID vaccine and menstrual cycles. They've gotten...